Review: α1-Antitrypsin deficiency associated liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 5, 1997, Pages 404-416

  Qu, Dongfeng ^b   Teckman, Jeffrey H ^b   Perlmutter, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

endoplasmic reticulum degradation; liver disease

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENETIC DISORDER; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS;

EID: 0030922043     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00451.x     Document Type: Review

References (99)

1. Perlmutter DH. Liver disease in α1-antitrypsin deficiency. In: Ockner RK, Boyer J, eds. Progress in Liver Disease, vol. IX. Philadelphia: WB Saunders, 1993; 139-65.
2. Wilson E, Cox D. Alpha-1-antitrypsin deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill Inc., 1989; 2409-37.
3. 1-Antitrypsin deficiency: Prevalence estimation from direct population screening. Am. Rev. Respir. Dis. 1989; 140: 961-6.
4. 1-antitrypsin PiZ. FEBS Lett. 1976; 65: 195-7.
5. Owen MC, Carrell RW. Alpha-1-antitrypsin: Sequence of the Z variant tryptic peptide. FEBS Lett. 1976; 79: 247-9.
6. 1-antitrypsin variant (PiZ) associated with plasma activity efficiency. Proc. Natl Acad. Sci. USA 1976; 73: 1324-8.
7. Kidd VJ, Wallace RB, Itakura K, Woo SLC. Alpha-1-antitrypsin deficiency detection by analysis of mutation of the gene. Nature 1983; 304: 230-4.
8. 1-proteinase inhibitor deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc. Natl Acad. Sci. USA 1985; 82: 6918-21.
9. 1-antitrypsin deficient individuals. J. Clin. Invest. 1986; 77: 1952-61.
10. 1-antitrypsin. FEBS Lett. 1984; 168: 84-8.
11. 1-antitrypsin does not prevent its synthesis and secretion. FEBS Lett. 1987; 216: 79-82.
12. 1-antitrypsin by addition of a second mutation. Science 1988; 242: 1700-2.
13. McCracken AA, Druse KB, Brown JL. Molecular basis for defective secretion of variants having altered potential for salt bridge formation between amino acids 240 and 342. Mol. Cell Biol. 1989; 9: 1408-14.
14. 1-antitrypsin variant. J. Biol. Chem. 1989; 264: 2997-3001.
15. 1-antitrypsin from Xenopus oocytes. FEBS Lett. 1990; 268:21-3.
16. 1-protease inhibitor mutants and the effect of these mutations on secretion of variant inhibitors. J. Biol. Chem. 1991; 266: 7578-82.
17. 1-Antitrypsin: Molecular pathology, leukocytes and tissue damage. J. Clin. Invest. 1986; 77: 1427-31.
18. 1-antitrypsin causes liver damage in transgenic mice. J. Clin. Invest. 1989; 83: 1183-90.
19. 1-antitrypsin: A transgenic mice model. Science 1988; 242: 1401-12.
20. 1-antitrypsin liver disease in a transgenic mouse model. Hepatology 1990; 12: 40-7.
21. 1-antitrypsin transgenic mice: Histopathological and DNA ploidy studies. Hepatology 1994; 19: 389-97.
22. 1-antitrypsin deficiency. Hepatology 1995; 22: 514-17.
23. 1-antitrypsin deficiency. Proc. Natl Acad. Sci. USA 1994; 91: 9014-18.
24. 2 subunit. J. Biol. Chem. 1996; 271: 13 215-20.
25. 1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J. Biol. Chem. 1996; 271: 22 791-5.
26. 1-antitrypsin deficiency in childhood. J. Pediatr. 1983; 102: 661-5.
27. 1-antitrypsin deficiency: Prognostic indicators. J. Pediatr. 1990; 117: 864-70.
28. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder. J. Lab. Clin. Med. 1969; 73: 934-9.
29. 1-antitrypsin deficiency. N. Engl. J. Med. 1989; 314: 736-9.
30. 1-antitrypsin deficiency detected by screening of 200 000 infants. N. Engl. J. Med. 1976; 294: 1216-21.
31. 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N. Engl. J. Med. 1981; 304: 357-60.
32. 1-antitrypsin deficiency identified by a PiZ-specific monoclonal antibody. Scand. J. Gastroenterol. 1985; 20: 835-42.
33. Vecchio FM, Fabiano A, Orsini G, Ragusa D, Massi G. Alpha-1-antitrypsin MZ phenotype and cryptogenic chronic liver disease in adults. Digestion 1983; 27: 100-4.
34. 1-antitrypsin deficiency and chronic liver disease. Ann. Intern. Med. 1992; 117: 641-5.
35. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and sindbis viruses. J. Virol. 1994; 68: 6147-60.
36. Dubussion J, Rice CM. Hepatitis C virus glycoprotein folding: Disulfide bond formation and association with calnexin. J. Virol. 1996; 70: 778-86.
37. 1-antitrypsin deficiency allele M Malton. J. Biol. Chem. 1989; 264: 13 938-45.
38. 1-antitrypsin. Gastroenterology 1987; 93: 181-7.
39. 1-antitrypsin deficiency PiM/PiM duarte. Gastroenterology 1987; 93: 242-4.
40. Mowat AP. Hepatitis and cholestasis in infancy: Intra-hepatic disorders. In: Mowat AP ed. Liver Disorder in Childhood. London: Butterworths, 1992; 43-58.
41. Qizibash A, Yong-Pong O. Alpha-1-antitrypsin liver disease: Differential diagnosis of PAS-positive diastase-resistant globules in liver cells. Am. J. Clin. Pathol. 1983; 79: 697-702.
42. Filipponi F, Soubrane O, Labrousse F et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: Pretransplant natural history, timing and results of transplantation. J. Hepatol. 1994; 20: 72-8.
43. Casavilla FA, Reyes J, Tzakis A et al. Liver transplantation for neonatal hepatitis as compared to the other two leading indications for liver transplantation in children. J. Hepatol. 1994; 21: 1035-9.
44. 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 1987; 316: 1055-62.
45. 1-antitrypsin deficiency. J. Clin. Invest. 1989; 84: 1349-54.
46. Wilson JM. Gene therapy for cystic fibrosis: Challenges and future directions. J. Clin. Invest. 1995; 96: 2547-54.
47. Wilson JM. Molecular medicine: Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 1996; 335: 1185-7.
48. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
49. Melnick J, Dul JL, Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 1994; 370: 373-5.
50. Castanotto D, Rossi JJ, Sarver N. Antisense catalytic RNAs as therapeutic agents. Adv. Pharmacol. 1994; 25: 289-317.
51. Askari FK, McDonnell WM. Molecular medicine: Antisense-oligonucleotide therapy. N. Engl. J. Med. 1996; 334: 316-18.
52. Teckman JH, Perlmutter DH. Conceptual advances in the pathogenesis and treatment of childhood metabolic liver disease. Gastroenterology 1995; 108: 1263-79.
53. 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-7.
54. 1-proteinase inhibitor probed by limited proteolysis. Biochemistry 1992; 31: 2720-8.
55. 1-antitrypsin for structure and function of serpins. Biochemistry 1990; 117: 48-53.
56. iiyama (Ser53 → Phe): Further evidence for intracellular loop-sheet polymerization. J. Biol. Chem. 1993; 268: 15 333-5.
57. 52deleted) forms loop-sheet polymers in vivo: Evidence for the C-sheet mechanism of polymerization. J. Biol. Chem. 1995; 270: 16 864-74.
58. 1-antitrypsin causes a protein folding defect. Nature Struct. Biol. 1995; 2: 363-7.
59. Hurtley SM, Helenius A. Protein oligomerization in the endoplasmic reticulum. Annu. Rev. Cell Biol. 1989; 5: 277-307.
60. Tatu U, Hammond C, Helenius A. Folding and oligomerization of influenza hemagglutinin in the ER and the intermediate compartment. EMBO J. 1995; 7: 1340-8.
61. 1-antitrypsin suppresses the folding defect of the Z-type variant. J. Biol. Chem. 1995; 270: 8597-601.
62. 1-antitrypsin deficiency variants. J. Biol. Chem. 1995; 270: 8393-6.
63. Eldering E, Verpy E, Roem D, Meo T, Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J. Biol. Chem. 1995; 270: 2579-87.
64. Rothman JE, Wieland FT. Protein sorting by transport vesicles. Science 1996; 272: 227-34.
65. Bednarek SY, Ravazzola M, Hosobuchi M et al. COPI- and COPII-coated vesicles bud directly from the endoplasmic reticulum in yeast. Cell 1995; 83: 1183-96.
66. Schimmoller F, Singer-Kruger B, Schroder S, Kruger U, Barlowe C, Reizman H. The absence of Emp24p, a component of ER-derived COPII-coated vesicles, causes a defect in transport of selected protein to the Golgi. EMBO J. 1995; 14: 1329-39.
67. Stamnes MA, Craighead MW, Hoe MH et al. An integral membrane component of coatomer-coated transport vesicles defines a family of proteins involved in budding. Proc. Natl Acad. Sci. USA 1995; 92: 8011-15.
68. Gething M-J, Sambrook J. Protein folding in the cell. Nature 1992; 355: 34-45.
69. 1antitrypsin gene of human cells by targeted homologous recombination. Lab. Invest. 1994; 70: 676-83.
70. Kuznetsov G, Chen LB, Nigam SK. Several endoplasmic reticulum stress proteins, including ERp72, interact with thyroglobulin during its maturation. J. Biol. Chem. 1994; 269: 22 990-5.
71. Degen W, Williams DB. Participation of a novel 88 kDa protein in the biogenesis of murine class histocompatibility molecules. J. Cell Biol. 1991; 112: 1099-115.
72. Hochstenbach F, David V, Watkins J, Brenner MB. Endoplasmic reticulum resident protein of 90 kilodaltons associates with T- and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc. Nad Acad. Sci. USA 1992; 89: 4734-8.
73. Ou W-J, Cameron PH, Thomas DY, Bergeron JJM. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature 1993; 364: 771-6.
74. 2 oligosaccharide as an initial step in recognizing unfolded glycoproteins. J. Biol. Chem. 1995; 270: 4697-704.
75. Herbert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 1995; 81: 425-53.
76. Sousa MC, Ferrero-Garcia MA, Parodi AJ. Recognition of the oligosaccharide and protein moieties of glycoproteins by the UDP-glucose:glycoprotein glucosyltransferase. Biochemistry 1992; 31: 97-105.
77. Bonifacino JS, Suzuki CK, Lippincott-Schwartz J, Weissman AM, Klausner RD. Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: Intrinsic sensitivity and the role of subunit assembly. J. Cell Biol. 1989; 109: 73-83.
78. Raposo G, van Santen HM, Liejendekker R, Geuze HJ, Ploegh HL. Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-GoIgi intermediate compartment. J. Cell Biol. 1995; 131: 1403-19.
79. 1-antitrypsin deficiency. Hepatology 1991; 13: 172-85.
80. Owen MC, Carrell RW. Alpha-1-antitrypsin: Molecular abnormality of S variant. BMJ 1976; 1: 130-1.
81. Cheng SH, Gregory RJ, Marshall J et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-34.
82. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 121-7.
83. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995; 83: 129-35.
84. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 1992; 61: 761-807.
85. Jackson MR, Cohen-Doyle MF, Petersen PA, Williams DB. Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90). Science 1994; 263: 384-7.
86. Bergeron JJM, Brenner MB, Thomas DY, Williams DB. Calnexin: A membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem. Sci. 1994; 19: 124-8.
87. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993; 365: 264-7.
88. Chisari FV, Klopchin K, Moriyama T et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-56.
89. Chisari FV. Hepatitis B virus transgenic mice: Insights into the virus and the disease. Hepatology 1995; 22: 1317-25.
90. Bathurst IC, Errington DM, Foreman RC, Judah JD, Carrell RW. Human Z alpha-1-antitrypsin accumulates intracellularly and stimulates lysosomal activity when synthesized in the Xenopus oocyte. FEBS Lett. 1985; 183: 304-8.
91. Dunn WA. Studies on the mechanism of autophagy: Formation of autophagic vacuole. J. Cell Biol. 1991; 110: 1923-33.
92. Seglen PO, Gordon P. Amino acid control of autophagic sequestration and protein degradation in isolated rat hepatocytes. J. Cell Biol. 1984; 99: 435-44.
93. Cox JS, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1994; 73: 1197-206.
94. Mori K, Ma W, Gething M-J, Sambrook J. A transmembrane protein with a cdc2+/CDC28-related kinase activity is required for signaling from the ER to the nucleus. Cell 1993; 74: 743-56.
95. Batchvarova N, Wang X-Z, Ron D. Inhibition of adipogenesis by the stress-induced protein CHOP (gadd153). EMBO J. 1995; 14: 4654-61.
96. Pahl HL, Sester M, Gurgert H-G, Baeuerle PA. Activation of transcription factor NF-κB by the adenovirus E3/19K protein requires its ER retention. J. Cell Biol. 1996; 132: 511-22.
97. 1-antitrypsin deficiency and liver disease. J. Clin. Invest. 1989; 84: 1555-61.
98. Gerner EW, Schneider MJ. Induced thermal resistance in HeLa cells. Nature 1975; 256: 500-3.
99. Carrell RW, Evans DL, Stein DE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576.